GYRE — GYRE THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1124105 ·
Last close
$4.56
Market Cap
$488.23M
52W High
$9.14
52W Low
$3.97
ADV30
191,062
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 32,934,000 | 30,987,000 | -1,470,000 | -4,053,000 | 201,251,000 | 41,643,000 | 56,734,000 |
| Jun 2026 | 29,105,000 | 26,896,000 | -13,861,000 | -10,605,000 | 199,255,000 | 43,287,000 | 56,766,000 |
| Mar 2026 | 22,519,000 | 21,292,000 | -6,802,000 | -8,691,000 | 162,015,000 | 37,501,000 | 25,030,000 |
| Dec 2025 | 37,195,000 | 35,452,000 | 120,000 | -1,723,000 | 166,132,000 | 37,070,000 | 23,850,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,935,000
Investing CF
$2,907,000
Financing CF
$2,802,000
CapEx
$-2,213,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.21
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-137,962,000
Inventory
$11,428,000
Receivables
$28,247,000
ST Investments
$31,509,000
EBIT TTM
$-13,617,000
Pretax Income TTM
$-16,108,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$110,058,000
EBITDA
$-13,450,000
Free Cash Flow
$1,875,250
Enterprise Value
$500,726,656
Total Cash
$70,044,000
Total Debt
$3,010,000
Shares Out
107,068,625
Trailing EPS
$-0.31
Book Value
$1.01
ROE
-17.2%
ROA
-6.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 116,588,000 | 11,491,000 | 5,027,000 | 166,132,000 | 23,850,000 | 106,031,000 | 1,010,000 |
| Dec 2024 | 105,757,000 | 16,229,000 | 12,085,000 | 125,406,000 | 27,004,000 | 63,319,000 | -3,641,000 |
| Dec 2023 | 113,450,000 | 19,213,000 | -92,933,000 | 116,539,000 | 102,590,000 | -15,828,000 | 25,892,000 |
| Dec 2022 | 102,290,000 | 9,203,000 | 2,302,000 | 84,753,000 | 12,536,000 | 42,522,000 | 10,677,000 |
TTM Snapshot
Revenues TTM
$119,383,000
NetIncome TTM
$-18,467,000
OpCashFlow TTM
—
Assets (Latest)
$199,255,000
Forward EPS
$0.06
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $4.34 · call volume: 1 · put volume: 3Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CAPR | CAPRICOR THERAPEUTICS, INC. | $488.98M | $8.41 | — |
| MNPR | Monopar Therapeutics | $481.56M | $71.06 | — |
| BLSM | BlossomHill Therapeutics, Inc. | $480.91M | $15.13 | — |
| IMMP | IMMUTEP Ltd | $480.43M | $3.26 | — |
| NGNE | Neurogene Inc. | $478.19M | $23.10 | — |
News headlines (Yahoo Finance, 1h cache)
Gyre Therapeutics, Inc. (GYRE) Tops Q3 Earnings and Revenue Estimates
2026-11-06 00:00 · Yahoo
Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates
2026-11-05 21:07 · Yahoo
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-03 11:00 · Yahoo
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates
2026-08-07 12:20 · Yahoo
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
2026-08-07 11:00 · Yahoo
Gyre Therapeutics Appoints Three New Members to its Board of Directors
2026-07-16 20:05 · Yahoo
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 11:45 · Yahoo
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
2026-05-07 10:00 · Yahoo
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
2026-05-12 20:05 · Yahoo
US High Growth Tech Stocks To Watch
2026-04-27 17:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.